Author archives: Zacks Equity Research

Biogen (BIIB) signs an agreement with Xbrane Biopharma for exclusive global rights to the latter’s biosimilar candidate, Xcimzane, referencing UCB’s arthritis drug, Cimzia.

Harley Davidson (HOG) reports higher year-over-year Q4 earnings on improved revenues across both segments.

CBRE Group, Jones Lang LaSalle and Cushman & Wakefield are included in this Industry Outlook blog.

Jacobs Engineering Group’s (J) fiscal Q1 results reflect the impact of the timing of large projects. Yet, double-digit backlog growth across all businesses depicts a potential upside.

Expedia’s (EXPE) Q4 results are likely to reflect gains from the growing bookings through Vrbo and increasing brand marketing. Yet, weak demand for leisure travel might have remained a negative.

Higher commodity price realizations and a stronger refining business aid BP’s Q4 earnings.

Universal Technical (UTI) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the…

Lear (LEA) delivered earnings and revenue surprises of 14.02% and 4.36%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Haemonetics (HAE) delivered earnings and revenue surprises of 12% and 2.58%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Aramark (ARMK) delivered earnings and revenue surprises of -4.35% and 4.28%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?